


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
BORTEZOMIB FOR INJECTION OBTAINS APPROVAL
FOR DRUG REGISTRATION**

This announcement is made by the board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that Bortezomib for Injection (comprising two specifications, 1.0mg and 3.5mg) (the “**Product**”), a generic drug developed by Chia-Tai Tianqing Pharmaceutical Holdings Co. Ltd, a subsidiary of the Company, has obtained approval for drug registration by the National Drug Administration of the People’s Republic of China. The Group has made further achievement in its continuous development of anti-tumor drugs.

Bortezomib as a proteasome inhibitor is a new anticancer drug in targeted therapy, being mainly used for treating multiple myeloma and mantle cell lymphoma and featuring with advantages of efficacy and safety (can be applied to patients with renal insufficiency or even renal failure). It has been proven in a number of international clinical studies that Bortezomib-containing regimens are more effective than traditional chemotherapy regimens, as they can significantly improve the patients’ complete response rate and extend their survival with improved quality of life. Bortezomib has been used as the preferred agent for front-line treatment of myeloma.

The Product will not only be a drug providing clinicians with another option for the treatment of myeloma, but also has great contribution to the society in reducing the treatment cost for patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairlady

Hong Kong, 20 July 2018

As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.